| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6107361 | Journal of Hepatology | 2009 | 9 Pages |
Abstract
Ras activation results from several molecular alterations, such as methylation of tumor suppressors and amplification of oncogenes (B-raf). Sorafenib blocks signaling and synergizes with rapamycin in vivo, preventing tumor progression. These data provide the rationale for testing this combination in clinical studies.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Pippa Newell, Sara Toffanin, Augusto Villanueva, Derek Y. Chiang, Beatriz Minguez, Laia Cabellos, Radoslav Savic, Yujin Hoshida, Kiat Hon Lim, Pedro Melgar-Lesmes, Steven Yea, Judit Peix, Kemal Deniz, M. Isabel Fiel, Swan Thung, Clara Alsinet,